| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Sarah Cannon Cancer Center and Tennessee Oncology, Nashville, Tennessee, USA
Correspondence: Howard A. Burris III, M.D., F.A.C.P., Sarah Cannon Cancer Center, 250 25th Avenue North, Suite 110, Nashville, Tennessee 37203, USA. Telephone: 615-986-4300; Fax: 615-986-0029; e-mail: hburris{at}tnonc.com
Dual inhibition of ErbB-1 (EGFR) and ErbB-2 (HER-2) tyrosine kinases has been found to exert greater biologic effects in the inhibition of signaling pathways promoting cancer cell proliferation and survival than inhibition of either receptor alone. The novel dual EGFR/ErbB-2 tyrosine kinase inhibitor lapatinib (GlaxoSmithKline; Research Triangle Park, NC) has been shown to inhibit tumor cell growth in vitro and in xenograft models for a variety of human tumors. Preliminary findings in a phase I study of lapatinib in patients with solid tumors indicate doses up to 1,800 mg per day are well tolerated. No grade 4 toxicities were observed and only two of 43 patients had grade 3 toxicity (diarrhea). Clinical activity of lapatinib was observed in these patients; nine patients with a variety of tumors remained on study for
4 months, one with a complete response (head and neck cancer). In a phase IB study in pretreated metastatic cancer patients with disease that could be biopsied, grade 1 or 2 diarrhea and rash were the most common adverse events. Three patients with breast cancer refractory to trastuzumab (Herceptin®; Genentech, Inc.; South San Francisco, CA) had partial responses and 12 patients with a variety of tumors had stable disease. Assessment of biologic correlates in these patients indicates that increased tumor cell apoptosis on the terminal deoxynucleotide transferase-mediated dUTP nick-end labeling assay correlates with clinical response. Lapatinib currently is being evaluated in phase II and phase III trials in patients with metastatic breast cancer.
This article has been cited by other articles:
 |
|
 |
|
  Q. S.C. Chu, M. E. Cianfrocca, L. J. Goldstein, M. Gale, N. Murray, J. Loftiss, N. Arya, K. M. Koch, L. Pandite, R. A. Fleming, et al. A Phase I and Pharmacokinetic Study of Lapatinib in Combination with Letrozole in Patients with Advanced Cancer Clin. Cancer Res., July 15, 2008; 14(14): 4484 - 4490. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. M. LoRusso, S. F. Jones, K. M. Koch, N. Arya, R. A. Fleming, J. Loftiss, L. Pandite, S. Gadgeel, B. L. Weber, and H. A. Burris III Phase I and Pharmacokinetic Study of Lapatinib and Docetaxel in Patients With Advanced Cancer J. Clin. Oncol., June 20, 2008; 26(18): 3051 - 3056. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. R. Siemens, N. Hu, A. K. Sheikhi, E. Chung, L. J. Frederiksen, H. Pross, and C. H. Graham Hypoxia Increases Tumor Cell Shedding of MHC Class I Chain-Related Molecule: Role of Nitric Oxide Cancer Res., June 15, 2008; 68(12): 4746 - 4753. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Wangpaichitr, N. Savaraj, J. Maher, M. Kurtoglu, and T. J. Lampidis Intrinsically lower AKT, mammalian target of rapamycin, and hypoxia-inducible factor activity correlates with increased sensitivity to 2-deoxy-D-glucose under hypoxia in lung cancer cell lines Mol. Cancer Ther., June 1, 2008; 7(6): 1506 - 1513. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Vazquez-Martin, C. Oliveras-Ferraros, R. Colomer, J. Brunet, and J. A. Menendez Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb(R)) in human breast carcinoma cells Ann. Onc., June 1, 2008; 19(6): 1097 - 1109. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. T. Winnard Jr., A. P. Pathak, S. Dhara, S. Y. Cho, V. Raman, and M. G. Pomper Molecular Imaging of Metastatic Potential J. Nucl. Med., June 1, 2008; 49(Suppl_2): 96S - 112S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Elser, L. Borsig, P. O. Hassa, S. Erener, S. Messner, T. Valovka, S. Keller, M. Gassmann, and M. O. Hottiger Poly(ADP-Ribose) Polymerase 1 Promotes Tumor Cell Survival by Coactivating Hypoxia-Inducible Factor-1-Dependent Gene Expression Mol. Cancer Res., February 1, 2008; 6(2): 282 - 290. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Palmowski, J. Huppert, G. Ladewig, P. Hauff, M. Reinhardt, M. M. Mueller, E. C. Woenne, J. W. Jenne, M. Maurer, G. W. Kauffmann, et al. Molecular profiling of angiogenesis with targeted ultrasound imaging: early assessment of antiangiogenic therapy effects Mol. Cancer Ther., January 1, 2008; 7(1): 101 - 109. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Widakowich, G. de Castro Jr., E. de Azambuja, P. Dinh, and A. Awada Review: Side Effects of Approved Molecular Targeted Therapies in Solid Cancers Oncologist, December 1, 2007; 12(12): 1443 - 1455. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Li and H. E. Schellhorn New Developments and Novel Therapeutic Perspectives for Vitamin C J. Nutr., October 1, 2007; 137(10): 2171 - 2184. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. S.C. Chu, G. Schwartz, J. de Bono, D. A. Smith, K. M. Koch, M. J. Versola, L. Pandite, N. Arya, J. Curtright, R. A. Fleming, et al. Phase I and Pharmacokinetic Study of Lapatinib in Combination With Capecitabine in Patients With Advanced Solid Malignancies J. Clin. Oncol., August 20, 2007; 25(24): 3753 - 3758. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Moy and P. E. Goss Lapatinib-Associated Toxicity and Practical Management Recommendations Oncologist, July 1, 2007; 12(7): 756 - 765. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. S. Lalani, S. E. Alters, A. Wong, M. R. Albertella, J. L. Cleland, and W. D. Henner Selective Tumor Targeting by the Hypoxia-Activated Prodrug AQ4N Blocks Tumor Growth and Metastasis in Preclinical Models of Pancreatic Cancer Clin. Cancer Res., April 1, 2007; 13(7): 2216 - 2225. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Tripathy Capecitabine in Combination with Novel Targeted Agents in the Management of Metastatic Breast Cancer: Underlying Rationale and Results of Clinical Trials Oncologist, April 1, 2007; 12(4): 375 - 389. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. T. Jorgensen, K. V. Nielsen, and B. Ejlertsen Pharmacodiagnostics and Targeted Therapies--A Rational Approach for Individualizing Medical Anticancer Therapy in Breast Cancer Oncologist, April 1, 2007; 12(4): 397 - 405. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Marzi, M. D'Amico, T. Biagiotti, S. Giunti, M. V. Carbone, D. Fredducci, E. Wanke, and M. Olivotto Purging of the Neuroblastoma Stem Cell Compartment and Tumor Regression on Exposure to Hypoxia or Cytotoxic Treatment Cancer Res., March 15, 2007; 67(6): 2402 - 2407. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Ratnam and J. A. Low Current Development of Clinical Inhibitors of Poly(ADP-Ribose) Polymerase in Oncology Clin. Cancer Res., March 1, 2007; 13(5): 1383 - 1388. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S Beslija, J Bonneterre, H Burstein, V Cocquyt, M Gnant, P Goodwin, V Heinemann, J Jassem, W. Kostler, M Krainer, et al. Second consensus on medical treatment of metastatic breast cancer Ann. Onc., February 1, 2007; 18(2): 215 - 225. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Moy and P. E. Goss Lapatinib: Current Status and Future Directions in Breast Cancer Oncologist, November 1, 2006; 11(10): 1047 - 1057. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Martin-Oliva, R. Aguilar-Quesada, F. O'Valle, J. A. Munoz-Gamez, R. Martinez-Romero, R. Garcia del Moral, J. M. Ruiz de Almodovar, R. Villuendas, M. A. Piris, and F. J. Oliver Inhibition of Poly(ADP-Ribose) Polymerase Modulates Tumor-Related Gene Expression, Including Hypoxia-Inducible Factor-1 Activation, during Skin Carcinogenesis Cancer Res., June 1, 2006; 66(11): 5744 - 5756. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Yin, A. Hashimoto, M. Izawa, K. Miyazaki, G.-Y. Chen, H. Takematsu, Y. Kozutsumi, A. Suzuki, K. Furuhata, F.-L. Cheng, et al. Hypoxic culture induces expression of sialin, a sialic Acid transporter, and cancer-associated gangliosides containing non-human sialic Acid on human cancer cells. Cancer Res., March 15, 2006; 66(6): 2937 - 2945. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Tajima, K. Schonherr, S. Niedling, M. Kaatz, H. Kanno, R. Schonherr, and S. H. Heinemann Ca2+-activated K+ channels in human melanoma cells are up-regulated by hypoxia involving hypoxia-inducible factor-1{alpha} and the von Hippel-Lindau protein J. Physiol., March 1, 2006; 571(2): 349 - 359. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Amir, R. Wang, H. Matzkin, J. W. Simons, and N. J. Mabjeesh MSF-A Interacts with Hypoxia-Inducible Factor-1{alpha} and Augments Hypoxia-Inducible Factor Transcriptional Activation to Affect Tumorigenicity and Angiogenesis Cancer Res., January 15, 2006; 66(2): 856 - 866. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Hudis and S. Van Belle Introduction: Examining the Potential Impact of Anemia Treatment on Clinical Outcomes in Anemic Cancer Patients Oncologist, November 1, 2004; 9(suppl_5): 1 - 3. [Full Text] [PDF]
|
|
|
|
|
|
P. Vaupel and L. Harrison Tumor Hypoxia: Causative Factors, Compensatory Mechanisms, and Cellular Response Oncologist, November 1, 2004; 9(suppl_5): 4 - 9. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Farrell and A. Lee The Erythropoietin Receptor and Its Expression in Tumor Cells and Other Tissues Oncologist, November 1, 2004; 9(suppl_5): 18 - 30. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Harrison and K. Blackwell Hypoxia and Anemia: Factors in Decreased Sensitivity to Radiation Therapy and Chemotherapy? Oncologist, November 1, 2004; 9(suppl_5): 31 - 40. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Ludwig, C. A. Hudis, G. Goss, and B. Leyland-Jones Epoetin Alfa: Future Directions and Future Research Oncologist, November 1, 2004; 9(suppl_5): 70 - 73. [Full Text] [PDF]
|
|
| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| THE ONCOLOGIST | STEM CELLS | CME | ALPHAMED PRESS JOURNALS |
